Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Relaxes Safety Requirements For Alzheimer's Trials, But Uncertainty Persists

Executive Summary

Sponsors and contract research organizations expressed cautious optimism about FDA's adoption of some of the recommendations of the Alzheimer's Association Research Roundtable Workgroup, but the agency isn't specifying which recommendations it is accepting.

You may also be interested in...

Alzheimer’s Plan Emphasizes Acceleration, Sets Timeline On Prevention, Cure

Ambitious draft plan from the Obama administration includes public/private efforts to shorten drug development times and pick up the pace of clinical trials, including more efficient ways of identifying and enrolling participants.

Boosting Study Enrollment While Protecting Alzheimer's Patients' Safety

Pipeline Of Alzheimer's Drugs Targeting Amyloid-Beta Protein

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts